RE:RE:RE:RE:RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A Pelareorep does not have any "product bundling" issues, since combination therapies for one indication are different from "bundling" different drugs with different indications being offered to wholesalers under the "take one and then take all" marketing / retailing scheme that Amgen has been noted for. "In its suit, the FTC argues that Amgen could leverage its lucrative portfolio of products to “entrench the monopoly positions” of Horizon’s thyroid eye disease drug Tepezza and gout treatment Krystexxa.
Amgen has a history of employing such bundling schemes with payers and pharmacy benefit managers (PBMs), the FTC argues. "
https://www.fiercepharma.com/pharma/request-ftc-amgen-agrees-delay-closure-278b-acquisition-horizon-until-september